Abstract 13786: Effectiveness of Ambulatory Pulmonary Artery Pressure-Guided Therapy in Reducing Readmissions in Patients With Heart Failure With Reduced Ejection Fraction versus Heart Failure With Preserved Ejection Fraction

Abstract

Listen

Translate article

Introduction: The cardio-microelectromechanical system (CardioMEMS) is an implantable pulmonary artery pressure monitoring device that aims to avoid decompensated heart failure (HF) admissions through hemodynamic-guided care. The aim of our study was to compare the impact of CardioMEMS implantation on hospital readmissions between HFrEF and HFpEF patients. Methods: Data from the National Readmission Database 2015 to 2019 were analyzed. International Classification of Diseases codes were used to identify patients hospitalized for HF and those with CardioMEMS implantation. The outcome of interest was the 30-day readmission rate. Multivariate logistic regression analysis was done to account for possible confounders. Results: We identified 3,801,661 admissions with a primary diagnosis of HF. Of these, 2,279,203 (59.95%) patients carried a diagnosis of HFrEF, while 1,522,458 (40.05%) had HFpEF. Patient characteristics are shown in the table. CardioMEMS was implanted in 1100 patients with HFrEF, and 297 patients with HFpEF. Among patients with HFrEF, those who received CardioMEMS implantation during the index admission had a significantly lower 30-day readmission rate compared to those who did not (16.4% vs 21.0%, adjusted odds ratio [OR] 0.74, 95% confidence interval [CI] 0.63-0.87, p <0.01) (Figure). However, among HFpEF patients, there was no significant reduction in 30-day readmissions after CardioMEMS implantation (19.8% vs 20.7%, adjusted OR 0.95, 95% CI 0.72-1.27, p = 0.37) (Figure). CardioMEMS implantation was not associated with a higher rate of complications such as major bleeding, acute kidney injury, or stroke, in both HFrEF and HFpEF groups. Conclusions: Our findings suggest that ambulatory pulmonary artery pressure-guided therapy may be more effective in reducing HF readmissions in patients with HFrEF than in those with HFpEF. This may have significant clinical implication in appropriate patient selection for CardioMEMS implantation.